AFFILIATIONS:
SITC, ESMO, AIOM, SIAPEC
LANGUAGES:
Italian (native speaker);
English (OET January 2025 Overall band score: B)
PUBLICATIONS:
1. Onofrio, L .; Gaeta, A.; O.; Cugliari, G.; Gandini, S.; Queirolo, P. Melanoma Brain Metastases: Immunotherapy or Targeted Therapy? A Systematic Review and Meta-Analyses. Appl. Sci.2024, 14,
2222. https://doi.org/10.3390/app14062222.
(As 1st author, I contributed to the selection of the literature papers and I was responsible for drafting the majority of the full text, excluding the statistical analyses).
2. Antonio Faiella, Ferdinando Riccardi, Giacomo Cartenì, Martina Chiurazzi, Livia Onofrio. The Emerging Role of c-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target, Journal of Oncology, vol. 2022, Article ID 5179182, 12 pages, 2022. https://doi.org/10.1155/2022/5179182.
(I was responsible for drafting the majority of the full text and bibliographic research).
3. Faiella A, Onofrio L , Liccardi F, Paladino F, Chiurazzi M, Riccardi F, Chiurazzi B. Oncological assistance in the emergency room setting: the role of a dedicated oncology unit. International Journal of Cancer Management.2021 Aug 14(7); e110512.
DOI: 10.5812/ijcm.110512.
(I actively contributed to the drafting of the paper by analyzing the data produced by Dr. Chiurazzi Bruno during his specialist consultations at the Emergency Room of Cardarelli Hospital in Naples).
4. Ferro M, Lucarelli G, Crocetto F, Dolce P, Verde A, La Civita E, Zappavigna S, de Cobelli O, Di Lorenzo G, Facchini BA, Scafuri L, Onofrio L, Porreca A, Busetto GM, Sonpavde G, Caraglia M, Klain M, Terracciano D, De Placido S, Buonerba C. First- line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. Crit Rev Oncol Hematol. 2020 Dec 13;157:103198. DOI: 10.1016/j.critrevonc.2020.103198. Epub ahead of print. PMID: 33316417.
(I contributed to literature research)
5. Di Lorenzo G, Zappavigna S, Crocetto F, Giuliano M, Ribera D, Morra R, Scafuri L,Verde A, Bruzzese D, Iaccarino S, Costabile F, Onofrio L , Viggiani M, Palmieri A, De Placido P, Marretta AL, Pietroluongo E, Luce A, Abate M, Navaeiseddighi Z, Caputo VF, Ce- lentano G,Longo N, Ferro M, Morelli F, Facchini G, Caraglia M, De Placido S, Buonerba C. Assessment of Total, PTEN-, and AR- V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide. Clin Genitourin Cancer. 2021 Oct;19(5):e286-e298. doi: 10.1016/j.clgc.2021.03.021. Epub 2021 Apr 3. PMID: 33958297.
(I participated to cancer patients care).
6. Galli F, Varani M, Lauri C, Silveri GG, Onofrio L, Signore A. Immune cell labelling and tracking: implications for adoptive cell transfer therapies. EJNMMI Radiopharm Chem.2021Feb 3;6(1):7.DOI:10.1186/s41181-020- 00116-7.PMID:33537909;PMCID: PMC7859135.
(I authored the section related to CAR-T and CAR-NK adoptive therapies).
7. Onofrio L , Caraglia M, Facchini G, Margherita V, De Placido S, Buonerba C. Toll-like receptors and COVID-19: a two-faced story with an exciting ending. Future Sci OA. 2020 Jul 30;6(8): FSO605. DOI:10.2144/fsoa20200091.PMID:32974046;PMCID: PMC7434222.
(Dr. Buonerba and I were the principal authors, contributing equallyto the writing of this paper).
8. Signore A, Lauri C, Auletta S, Varani M, Onofrio L, Glaudemans W.J.M. A, Panzuto F and Marchetti P. Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the choice of therapy. Cancers 2020, 12(4), 781; DOI:10.3390/cancers12040781.
(I contributed by providing my clinical expertise in medical oncology).
9. Onofrio L, Buonerba C, Isoquercetin in bladder cancer: a perspective of current potential uses in clinical practice and future directions in clinical research, (2019) Journal of Genitourinary Research and Practice, 1 (2), pp. 27-30. https://doi.org/10.15866/irege.v1i2.18914.
10. A Facciorusso, M Stanislao, C Vigna, V Triggiani, E Guastamacchia, L Onofrio and G Valle.Tako- Tsubo Cardiomyopathy: An Underdiagnosed Disease? BAOJ Pall Medicine 2017.3:12:025..
(I presented this paper at the 6th International Research Conference in Manchester in August 2016).
OTHER PUBLICATIONS:
"Lo streben e l'insonnia" - Booksprint Edizioni, 2013 "VOCEVERSO - Il fare del poeta" (Libraduepuntozero Ed. 2015)
Co-authorship with F Riccardi: First-Line Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer: A Case of Endocrine Resistance. Case report n. 8. Treatment of Breast Cancer with Abemaciclib: Clinical Practice Experiences. Vol II. Journal Edited by M De- Laurentiis & S De Placido
CONFERENCE ABSTRACTS:
L Onofrio, S Crossley, D J White, S Vimal, A Clipson, C Dive, S Valpione, F Mouliere Impact of Freeze-Thaw Cycles on cfDNA Quality in Liquid Biopsy.
(Poster presentations: Colloquium, Buxton, UK. October 9th-11th; Bicentennial of the School of Medical Sciences, Manchester 17th December 2024).
L Onofrio, A Gaeta, O, S Gandini, P Queirolo. 25th AIOM National Congress. 10th-12th Nov 2023. Mela- noma brain metastases: immunotherapy or target therapy? A systematic review and meta- analyses.
Castelli S., Arasi S., Tripodi S., Villalta D., Martelli P., Conte M., Panetta V., Simonelli I., Rohrbach A., Di Fraia M., Sfika I., Villella V., Di Rienzo BusincoA., Perna S., Dramburg S., Potapova E., OnofrioL., R. andMatricardi detection of IgE to allergenic molecules in nasal secretions: implications for the diagnosis of allergic rhino- conjunctivitis. Allergology and Clinical Immunology Nov 28-30, 2019, Matera (Italy), DOI: 10.13140/RG.2.2.13773.18402.
Onofrio L , Valle G, Stanislao M, Facciorusso A. Tako Tsubo Prevalence. World Journal of Medical Education and Research.
SPEAKER IN NATIONAL CONFERENCES:
Milan, 16th Feb 2024: PATRON: upgrading skills through collaboration. Management of patients treated with immunotherapy.
9th March 2022 Webinar live: 2nd season. Stories of melanoma: from adjuvant to metastatic;
2nd March 2021. 1st AIMS National Congress on Scientific Research and Development in the era of medical multidisciplinarity;
16th Dec 2020. 15th Health Forum Risk Management. Good practise in the era of COVID.
PUBLICATION I REVIEWED:
Wang L, HensleyCR, Howell ME, Ning S. Bioinformatics-Driven Identification of p62 as a Crucial Oncogene in Liver Cancer. Front Oncol. 2022 Jun 24;12:923009. doi: 10.3389/fonc.2022.923009. PMID: 35814476; PMCID: PMC9263135.
Monaca F, Vita E, Lococo F, et al. (July 23, 2024) Lazarus Response to Selpercatinib for Bleeding Colic Metastasis in a Patient With RET Fusion-Positive Pulmonary Sarcomatoid Carcinoma: A Case Report. Cureus 16(7): e65186. doi:10.7759/cureus.65186.
GRANTS:
SITC Spring Cellular Therapy for Solid Tumors (12th-14thMarch of2025,Virtual from San Diego,CA)
AFFILIATIONS:
CoLFS Award from University of Manchester, United Kingdom £2000,00 (Aug 2024)
ESMO Preceptorship in Gastric Cancer, Lisbon, Portugal 09/2024
ESMO Course on Precision Oncology in Oncogene-Addicted NSCLC: BRAF, KRAS, Rare EGFR, 09/2023
Erasmus International Thesis Scholarship, €2000 (July2017).
TRAININGS:
March- April 2024: Radiotherapy Complex Operational Unit, Policlinico Tor Vergata;
Jan - Feb 2024: Emergency: First Aid C omplex Operational Unit, Policlinico Tor Vergata.
Nov-Dec 2023 Palliative Care: ESMO Designed Centre San Raffaele S.p.A. Hospice Cassino.
Nov 2023 PhD Course: Mechanisms of Cancer, Cancer Biology &Translational Cancer Research, Univ. of Copenhagen.
8th-10th October 2019. Microbes, immunity and cancer, Ruggero Ceppellini Immunology School, Capri.
2018- 2019 Italian Academy of Resident Doctors (AIMS)
9th - 10th Feb 2019 Workshop: Labelling of Autologous Leukocytes with Leukokit® University.
Oct - Dec 2017 Internal Medicine Internship (Immunology and Rheumatology, Sant'Andrea Hospital
Aug 2016. Future Excellence 8th International Medical Summer School, Doctors Academy,University of Manchester (UK).
Sept 2010- Sept 2011. Biotechnology Course at the University of Rome La Sapienza.
EDUCATIONAL EVENTS:
Rome, 7th Oct 2018. Cancer prevention and fundraising: "Bikers vs Cancer" hosted by "Due ruote per la speranza" association.
Specialist Register GMC Reference n. 8097637(starting from 11/03/2025)
OM RM M 63843 (starting from 15/03/2018)
I participated in both diagnostic and research activities, under the supervision of Prof. Umberto Malapelle. I shadowed scientists and I gained experience in liquid biopsy, NGS (Ion Torrent®), qPCR (LightCycle TaqMan™ Gene Expression Assays,
cfDNA manual extraction; sequencing DNA/RNA quantification using Qubit Fluorometer; nanocapillary multifluidic platform 4200 TapeStation (Agilent Technologies) for evaluating quality and quantity of cfDNA from liquid biopsy and tissue samples
(e.g. microsatellites instability profile, MSI); mutation testing in solid tumors with NGS, dPCR,and RT-PCR; immune-profile and tumor-characterization with IHC;
Expanded gene panels integration into clinical practice;
NGS platforms & library preparation (Genexus, Illumina, Thermo Fisher, SOPHiA DDM); HRD, BRCA & methylation profiling (Oncomine, Hedera, Amoy Dx);
Tumor mutational burden (TMB) analysis (Oncomine TML assay); MSI-H/dMMR assessment (Idylla™, TapeStation 4200, IHC);
Use of SiRe panel (568 mutations in EGFR, KRAS, NRAS, BRAF, cKIT, PDGFRα);
Use of Nexthyro panel (15 genes for thyroid tumorigenesis, 100% specificity, 2% sensitivity).
I am responsible for devices and drugs check-list and medical prescriptions.
I supervise the private ambulance service and the staff, providing continuous professional development opportunities and recognized training (e.g. BLSD courses) to maintain and strengthen competencies.
I served as Ambulance's Medical Doctor during during sports competitions (Series A and B water polo matches, swimming-pool, synchronized swimming, lifesaving swimming events, marathons, bikes competitions and football matches, and horse-riding).
As a medical oncology resident, within 5-year residency I had the opportunity to gain experience in both laboratory and clinical settings:
1st year. Dept. of Onco-Haematology, Diagnostic Imaging and Morphology, and Legal Medicine at the Policlinic Federico II of Naples
I was involved in laboratory activities at the Department of Clinical Medicine and Surgery, University of Naples Federico II , under the supervision of Prof Roberto Bianco, who was working on experiments evaluating resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer and also on synergistic inhibition of human pancreatic cancer cell growth combining cytotoxic drugs with anti-sense oligonucleotides targeting protein-kinases.
I served as resident at the Centre of expertise for rare tumors. I also worked for two months in the department of medical oncology at Cardarelli Hospital , where I participated in multidisciplinary team meetings and gained experience in publishing peer-reviewed papers.
2nd year. University of Rome La Sapienza. Dept. of Radiological, Oncological and Pathological Sciences, Policlinic Umberto I. served as general medical oncology trainee at the day hospital and clinics. I actively participated to multidisciplinary meetings for each group disease. I also completed a lab internship at the Department of Molecular Medicine , faculty of Medicine and Pharmacology, under the supervision of Prof Giuseppe Giannini. He was working on targets and mechanisms of MYCN-driven neuronal tumor development and STING reactivation in MYCN-driven in vitro models.
3rd year) University of Milan Statale. I broadened my experience in clinical research at the IRCSS European Institute of Oncology (IEO) in Milan, gaining extensive experience in phase I clinical trials under the guidance of Prof. Giuseppe Curigliano, as well as in phase II and III trials in the Melanoma and Sarcomas Department under the supervision of Prof. Paola Queirolo. This
invaluable experience provided me with significant expertise in managing and reporting experimental drugs-related toxicity and irAEs, monitoring patients enrolled in clinical trials. I participated to multidisciplinary teams meetings as well as to molecular tumor board meetings. I gave familiarity with decision-making aspects of personalized therapy, based on tumor-agnostic decision and the mutational profil identified in individual patients.
I also completed training in the Department of Medical Oncology, focusing on Urogenital and Head and Neck tumor treatments at the same institute.
I actively participated, also as speaker, in national meetings about management of immunotherapy in solid tumors, enabling me to build strong professional networks with other italian institutions.
Working within the Melanoma Team, I published as first author a meta-analysis and systematic review comparing the target therapy with the immunotherapy as the best treatment option for BRAF V600E melanoma metastatic to the brain. The abstract was presented in 2023 at the annual conference of Italian Association of Medical Oncology (AIOM).
4th & 5th year. University of Rome Tor Vergata, Policlinic Tor Vergata , Department of onco-haematology, Complex Operative Unit of Medical Oncology. I served as senior resident within the outpatient clinic, day hospital, and inpatient ward. I completed further training in: emergency medicine, clinical oncology, and palliative care at the ESMO designated Centre San Raffaele S.p.A (in Cassino and Rome).
I served as a ward physician. within the Department of Internal Medicine, carrying out patient examinations, updating medical records, and managing emergency situations. Moreover, I established strong relationships with nurse staff, patients and their families, fostering trust and commitment to the healthcare plan.
I served as vaccinating doctor for the COVID-19 pandemic within the vaccination centers of
Pantigliate - CV Esselunga Pantigliate and Vizzolo Predabissi, in Milan
(ASST Melegnano e della Martesana
Via Pandina, 1 – 20070 Vizzolo Predabissi)
I served as Medical Doctor within the Emergency Department and Public Ambulance Service within the hospitals of ULSS 6 Euganea:
Cittadella Hospital: 28, Via dei Pilastroni - 35013 Cittadella, Padua
Montagnana Hospital: 16, Via Ospedale - 35044
Montagnana, Pauda
I was in charge of the medical assistance in both emergency room and during ambulance transfers.
I served as on-call doctor
I served as on-call doctor in both sites:
30, Via Maresciallo Caviglia - 00195 Rome;
625, Via di Boccea - 00166 Rome
I shadowed scientist within the Immunotherapy Unit, Department of Research, Advanced Diagnostic and Technological Innovation of the Translational Research Functional Departmental Area in I.F.O. Hospital, Regina Elena National Cancer Institute in Rome.
Under the supervisor of Prof. Paola Nisticò, I gained proficiency in:
Setting up cancer cell cultures;
study of TILs (Tumor Infiltrating Lymphocytes) with electron microscope; study of cells with con focal microscope; FACs analysis of circulating lymphocytes; Western Blot and ELISA techniques;
Lymphocytes HLA-2 typing;
setting up CD8+T cells cultures with PHA.
I served as emergency doctor in emergency room at the Lanzo Hospital in 30, Via Dei Marchesi della Rocca - 10074 Lanzo Torinese, Turin.
I served as locum agency Medical Doctor at the private hospital in 6, Via dei Pioppi - 00172 Rome.
Clinical Biochemical Analysis Laboratory Unit - Department of Diagnostic Sciences.
Under the supervision of Prof. Maurizio Simmaco, I gained proficiency in:
Indirect Immunofluorescence in tissues for detection of human auto- antibodies (ANA, EMA, ICAs, SMAs, AMAs, anti-LMK, APCAs);
Immunoblot procedures for detecting extensive antibody profiles ENA.
Clinical Biochemical Analysis Laboratory Unit - Department of Diagnostic Sciences.
Under the supervision of Prof. Maurizio Simmaco, I gained proficiency in:
Indirect Immunofluorescence in tissues for detection of human auto- antibodies (ANA, EMA, ICAs, SMAs, AMAs, anti-LMK, APCAs);
Immunoblot procedures for detecting extensive antibody profiles ENA.
Clinical skills: cancer diagnosis and staging; treatment planning; patient care management, including palliative care; patient education and monitoring; managing cancer-related symptoms and drugs-related side effects; Multidisciplinary Team and Molecular Tumor Board meetings Cardiopulmonary resuscitation and use of BLS-D and PBLS-D(Last certified training updated to January 2025)
High-quality clinical evidence: Skilled in patient recruitment, protocol adherence, and safety assessments Navigating the Cochrane Library to extract and Experienced in conducting clinical work and research in compliance synthesize publications for systematic reviews and with GCP guidelines, ensuring ethical standards, patient safety, and data analysis
data integrity throughout clinical processes
Communication skills: Demonstrated strong communication abilities in both professional and team building settings Advanced communication proficiency essential for effectively discussing sensitive topics with cancer patients, as well as in scientific presentations
Analytics: use of python libraries for data analysis, use of Microsoft Excel for data collection and analysis
Technical Skills: Search Optimization: Proficient in advanced Google Search techniques and literature research using tools such as Research Rabbit, Scopus, PubMed, and clinical trial databases; Office Tools Design and Editing with Adobe Photoshop Proficient use of cloud-based tools
Cell and Molecular Biology Skills:
PBMCs isolation, cell culturing, and counting Sample storage in liquid nitrogen;
FACs analysis;
cfDNA extraction (manual and automatic systems) and quantification Use of TapeStation for cfDNA and MSI status analysis
DNA sequencing from liquid biopsy
precision in conducting experiments in adherence to SOPs;
Human Tissue Good Research Practice: MRC Certified in Oct 2024
Clinical and Research Standards:
Good Clinical Practice (GCP);
Data Protection and Cyber Security Research Integrity
Data and Samples Management:
Use of Laboratory Information Management System (LIMS) and Q-Pulse;
Laboratory Techniques and Assays: Multiplex ImmunoCAP ISAC microarray; auto-antibodies detection; Immunofluorescence;
RNase P; qPCR, RT-PCR
Personal Skills: Resilience and stress management;
highly proficient in maintaining;
composure and delivering results under stressful conditions, including managing strict deadlines, high-volume workloads, and emergency situations (eg, handling red codes in ambulance settings)
Adaptable to international travel and long-term relocations for study and work purposes, with proven ability to navigate and overcome cultural adjustment challenges
I am skilled at finding ways to achieve objectives within deadlines, even when operating with very limited financial resources
My skills include grantsmanship and fund-raising I am a highly adaptable and driven professional, eager to embrace new challenges, cultures, and environments
With a passionate curiosity and unwavering commitment to the field of immuno-oncology, I thrive in collaborative, team-oriented settings